Skip to content

Evaluation of the efficacy of stellate ganglion block in patients with anxiety disorders

Evaluation of the efficacy of stellate ganglion block in patients with anxiety disorders

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500112791
Enrollment
Unknown
Registered
2025-11-19
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety disorders

Interventions

Enrolled patients:6-10 interventions were given to patients with anxiety-related disorders with stellate ganglion block therapy, i.e., regional block with 2ml of 2% lidocaine injected into the loose c

Sponsors

The First People's Hospital of Yunnan Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age is 18~60 years old. 2. Meet the diagnostic criteria for anxiety disorders (including generalized anxiety disorder, panic disorder, placephobia, specific phobia, social anxiety disorder, etc.) in the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) [DSM-5]. 3. Hamilton Anxiety Scale (HAMA) score > 14 points at enrollment. 4. No contraindications to stellate ganglion block treatment. 5. Written informed consent and the consent of the Ethics Committee.

Exclusion criteria

Exclusion criteria: 1. Suffering from severe mental illness and requiring hospitalization, or unable to complete the required assessment and treatment. 2. have a high risk of self-harm or suicide. 3. Suffering from severe physical illness, neurological disease, or substance abuse. 4. Meet the diagnostic criteria for anxiety disorders while meeting the diagnostic criteria for other psychiatric disorders in DSM-5. 5. Previous experience of a major traumatic event or currently experiencing a major traumatic event. 6. Received systematic medication, psychotherapy, or physical therapy, or used drugs other than conventional anxiolytic medications within 3 months prior to enrollment. 7. Pregnant or lactating. 8. Those who cannot cooperate with functional near-infrared spectroscopy technical examination, stellate ganglion block treatment, functional near-infrared spectroscopy technical examination, and stellate ganglion block treatment are contraindicated; 9. Abnormal coagulation function and infection at the puncture site.

Design outcomes

Primary

MeasureTime frame
Hamilton Anxiety Scale (HAMA);Local brain area neural activity and brain functional status;

Countries

China

Contacts

Public ContactHuijie Tang

The First People's Hospital of Yunnan Province

dior.tang@163.com+86 15 982 527 9269

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026